Loading...
XASXCLV
Market cap43mUSD
Jan 06, Last price  
0.42AUD
1D
0.00%
1Q
-23.85%
Jan 2017
-20.19%
Name

Clover Corporation Ltd

Chart & Performance

D1W1MN
XASX:CLV chart
P/E
45.75
P/S
1.11
EPS
0.01
Div Yield, %
1.81%
Shrs. gr., 5y
0.06%
Rev. gr., 5y
-4.10%
Revenues
62m
-22.12%
17,470,00014,959,00018,037,00016,650,00021,697,00021,498,00034,937,00038,387,00044,098,00027,190,00029,921,00042,920,00047,864,00062,961,00076,682,00088,281,00060,505,00070,660,00079,875,00062,207,000
Net income
2m
-75.58%
-266,000-174,000453,000635,0004,135,0003,082,000-967,0004,371,0006,078,000967,000100,0002,213,0003,639,0007,588,00010,101,00012,487,0006,004,0007,133,0006,205,0001,515,000
CFO
8m
+25.50%
000000002,526,0003,198,0003,106,000-63,000-595,0004,081,0004,791,0006,661,0008,228,0005,934,0006,736,0008,454,000
Dividend
Oct 21, 20240.0075 AUD/sh
Earnings
Mar 18, 2025

Profile

Clover Corporation Limited refines and sells natural oils in Australia, New Zealand, Asia, Europe, and the Americas. It also engages in the production of encapsulated products; and research and product development of functional food and infant nutrition ingredients. In addition, the company offers Nu-Mega Hi docosahexaenoic tuna oils for use in infant formula and pharmaceutical products; Ocean Gold refined tuna oils; Nu-Mega Driphorm powders that are used in a range of infant formula, follow-on formula, growing up milks, and food applications; and Nu-Mega Driphorm HA for non-dairy applications. Further, it provides products in the areas of active living-immune system and sports, healthy living–brain and heart, and starting out-infant and child. The company was incorporated in 1988 and is headquartered in Altona North, Australia.
URL
https://www.clovercorp.com.au/en/
IPO date
Nov 30, 1999
Employees
48
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑072023‑072022‑072021‑072020‑072019‑072018‑072017‑072016‑072015‑07
Income
Revenues
62,207
-22.12%
79,875
13.04%
70,660
16.78%
Cost of revenue
58,212
70,591
59,544
Unusual Expense (Income)
NOPBT
3,995
9,284
11,116
NOPBT Margin
6.42%
11.62%
15.73%
Operating Taxes
402
2,156
2,707
Tax Rate
10.06%
23.22%
24.35%
NOPAT
3,593
7,128
8,409
Net income
1,515
-75.58%
6,205
-13.01%
7,133
18.80%
Dividends
(1,252)
(2,917)
(1,664)
Dividend yield
1.53%
1.60%
0.93%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
3,846
2,129
1,781
Long-term debt
8,460
11,476
10,297
Deferred revenue
1,893
1,054
Other long-term liabilities
58
37
20
Net debt
(11,204)
(7,494)
(9,849)
Cash flow
Cash from operating activities
8,454
6,736
5,934
CAPEX
(2,328)
(1,639)
(1,426)
Cash from investing activities
(2,971)
(2,529)
(1,426)
Cash from financing activities
(2,661)
(4,881)
(3,488)
FCF
8,169
2,597
4,836
Balance
Cash
12,259
9,437
10,111
Long term investments
11,251
11,662
11,816
Excess cash
20,400
17,105
18,394
Stockholders' equity
67,070
67,151
63,040
Invested Capital
57,115
61,201
56,464
ROIC
6.07%
12.12%
15.30%
ROCE
5.10%
11.69%
14.67%
EV
Common stock shares outstanding
166,999
166,999
166,439
Price
0.49
-55.05%
1.09
0.93%
1.08
-38.29%
Market cap
81,830
-55.05%
182,029
1.27%
179,754
-38.29%
EV
70,626
174,535
169,905
EBITDA
5,160
10,203
11,828
EV/EBITDA
13.69
17.11
14.36
Interest
899
730
455
Interest/NOPBT
22.50%
7.86%
4.09%